"Evaluation Of compliance To Iron Chelation Therapy With Defe-Roxamine In Patients With Major Thalassemia In Iran In 2004 "
Background and Aim: With the introduction of long term subcutaneous administration of Deferoxamine there has been a decline in the morbidity and mortality of transfusion-dependent beta thalassemia patients. But parenteral iron chelation therapy is still a burden and a major reason for unsatisfactory...
Main Authors: | M. Izadyar, L. Sedighipourand H. Jafarieh |
---|---|
Format: | Article |
Language: | fas |
Published: |
Tehran University of Medical Sciences
2006-06-01
|
Series: | Tehran University Medical Journal |
Subjects: | |
Online Access: | http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/2621.pdf&manuscript_id=2621 |
Similar Items
-
The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01) -
The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01) -
Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
by: Nuzzi R, et al.
Published: (2021-05-01) -
Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01) -
Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01)